Quest Diagnostics (DGX) Competitors

$187.80 -3.05 (-1.60%)

Closing price 03:59 PM Eastern

Extended Trading

$187.95 +0.15 (+0.08%)

As of 04:04 PM Eastern

DGX vs. HSIC, MEDP, AMN, LH, and DVA

Should you buy Quest Diagnostics stock or one of its competitors? MarketBeat compares Quest Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quest Diagnostics include Henry Schein (HSIC), Medpace (MEDP), AMN Healthcare Services (AMN), Labcorp (LH), and DaVita (DVA). These companies are all part of the "medical" sector.

How does Quest Diagnostics compare to Henry Schein?

Henry Schein (NASDAQ:HSIC) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Quest Diagnostics has lower revenue, but higher earnings than Henry Schein. Quest Diagnostics is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.38B	0.62	$398M	$3.31	21.95
Quest Diagnostics	$11.28B	1.84	$992M	$9.05	20.75

Quest Diagnostics has a net margin of 9.07% compared to Henry Schein's net margin of 2.95%. Quest Diagnostics' return on equity of 15.60% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
Quest Diagnostics	9.07%	15.60%	7.06%

Henry Schein has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are held by institutional investors. 0.9% of Henry Schein shares are held by insiders. Comparatively, 0.9% of Quest Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Henry Schein presently has a consensus target price of $86.83, suggesting a potential upside of 19.52%. Quest Diagnostics has a consensus target price of $216.58, suggesting a potential upside of 15.33%. Given Henry Schein's higher probable upside, research analysts clearly believe Henry Schein is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.36
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Quest Diagnostics had 7 more articles in the media than Henry Schein. MarketBeat recorded 18 mentions for Quest Diagnostics and 11 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.91 beat Quest Diagnostics' score of 0.72 indicating that Henry Schein is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Quest Diagnostics beats Henry Schein on 9 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to Medpace?

Medpace (NASDAQ:MEDP) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Quest Diagnostics has higher revenue and earnings than Medpace. Quest Diagnostics is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.68B	4.48	$451.12M	$15.91	26.39
Quest Diagnostics	$11.28B	1.84	$992M	$9.05	20.75

In the previous week, Medpace had 12 more articles in the media than Quest Diagnostics. MarketBeat recorded 30 mentions for Medpace and 18 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.72 beat Medpace's score of 0.21 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

78.0% of Medpace shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Medpace has a net margin of 17.19% compared to Quest Diagnostics' net margin of 9.07%. Medpace's return on equity of 120.89% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Quest Diagnostics	9.07%	15.60%	7.06%

Medpace currently has a consensus target price of $467.08, suggesting a potential upside of 11.25%. Quest Diagnostics has a consensus target price of $216.58, suggesting a potential upside of 15.33%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe Quest Diagnostics is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Medpace has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Summary

Medpace beats Quest Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Quest Diagnostics compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Quest Diagnostics (NYSE:DGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

AMN Healthcare Services currently has a consensus price target of $25.29, suggesting a potential downside of 16.57%. Quest Diagnostics has a consensus price target of $216.58, suggesting a potential upside of 15.33%. Given Quest Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Quest Diagnostics has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.43	-$95.70M	-$0.87	N/A
Quest Diagnostics	$11.28B	1.84	$992M	$9.05	20.75

In the previous week, AMN Healthcare Services had 5 more articles in the media than Quest Diagnostics. MarketBeat recorded 23 mentions for AMN Healthcare Services and 18 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.72 beat AMN Healthcare Services' score of 0.56 indicating that Quest Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	4 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 88.1% of Quest Diagnostics shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 0.9% of Quest Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

AMN Healthcare Services has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Quest Diagnostics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

Quest Diagnostics has a net margin of 9.07% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Quest Diagnostics	9.07%	15.60%	7.06%

Summary

Quest Diagnostics beats AMN Healthcare Services on 12 of the 17 factors compared between the two stocks.

How does Quest Diagnostics compare to Labcorp?

Quest Diagnostics (NYSE:DGX) and Labcorp (NYSE:LH) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

In the previous week, Quest Diagnostics had 8 more articles in the media than Labcorp. MarketBeat recorded 18 mentions for Quest Diagnostics and 10 mentions for Labcorp. Labcorp's average media sentiment score of 0.78 beat Quest Diagnostics' score of 0.72 indicating that Labcorp is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Labcorp	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quest Diagnostics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Quest Diagnostics has a net margin of 9.07% compared to Labcorp's net margin of 6.66%. Labcorp's return on equity of 16.29% beat Quest Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
Labcorp	6.66%	16.29%	7.62%

Quest Diagnostics has higher earnings, but lower revenue than Labcorp. Quest Diagnostics is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.28B	1.84	$992M	$9.05	20.75
Labcorp	$14.14B	1.47	$876.50M	$11.29	22.49

88.1% of Quest Diagnostics shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 0.9% of Quest Diagnostics shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Quest Diagnostics pays an annual dividend of $3.44 per share and has a dividend yield of 1.8%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Quest Diagnostics pays out 38.0% of its earnings in the form of a dividend. Labcorp pays out 25.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Quest Diagnostics has increased its dividend for 14 consecutive years. Quest Diagnostics is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Quest Diagnostics presently has a consensus price target of $216.58, suggesting a potential upside of 15.33%. Labcorp has a consensus price target of $308.00, suggesting a potential upside of 21.32%. Given Labcorp's stronger consensus rating and higher possible upside, analysts plainly believe Labcorp is more favorable than Quest Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Labcorp	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Summary

Labcorp beats Quest Diagnostics on 12 of the 19 factors compared between the two stocks.

How does Quest Diagnostics compare to DaVita?

Quest Diagnostics (NYSE:DGX) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Quest Diagnostics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, DaVita has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

In the previous week, DaVita had 1 more articles in the media than Quest Diagnostics. MarketBeat recorded 19 mentions for DaVita and 18 mentions for Quest Diagnostics. Quest Diagnostics' average media sentiment score of 0.72 beat DaVita's score of 0.71 indicating that Quest Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quest Diagnostics	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
DaVita	4 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

88.1% of Quest Diagnostics shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.9% of Quest Diagnostics shares are held by insiders. Comparatively, 1.5% of DaVita shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Quest Diagnostics presently has a consensus price target of $216.58, suggesting a potential upside of 15.33%. DaVita has a consensus price target of $199.17, suggesting a potential upside of 3.49%. Given Quest Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Quest Diagnostics is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quest Diagnostics	0 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Quest Diagnostics has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quest Diagnostics	$11.28B	1.84	$992M	$9.05	20.75
DaVita	$13.64B	0.91	$746.80M	$10.78	17.85

Quest Diagnostics has a net margin of 9.07% compared to DaVita's net margin of 5.65%. Quest Diagnostics' return on equity of 15.60% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quest Diagnostics	9.07%	15.60%	7.06%
DaVita	5.65%	-270.37%	4.87%

Summary

Quest Diagnostics beats DaVita on 10 of the 17 factors compared between the two stocks.

Get Quest Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DGX vs. The Competition

Export

Metric	Quest Diagnostics	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$20.79B	$5.57B	$6.29B	$23.00B
Dividend Yield	1.81%	1.56%	2.79%	4.07%
P/E Ratio	20.75	34.74	20.87	28.39
Price / Sales	1.84	22.75	521.62	39.21
Price / Cash	12.53	16.46	42.94	25.11
Price / Book	2.71	3.15	9.86	4.76
Net Income	$992M	$218.81M	$3.55B	$1.06B
7 Day Performance	-1.60%	-0.06%	-0.26%	-0.74%
1 Month Performance	-3.21%	3.72%	1.39%	1.74%
1 Year Performance	9.01%	20.20%	41.07%	25.05%

Quest Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DGX Quest Diagnostics	4.8804 of 5 stars	$187.80 -1.6%	$216.58 +15.3%	+9.1%	$20.79B	$11.28B	20.75	57,000	Analyst Revision
HSIC Henry Schein	3.7126 of 5 stars	$68.99 -2.6%	$86.83 +25.9%	-1.5%	$8.07B	$13.18B	20.84	25,000	Insider Trade
MEDP Medpace	3.1684 of 5 stars	$417.29 -1.6%	$467.08 +11.9%	+36.6%	$12.11B	$2.53B	26.23	6,200
AMN AMN Healthcare Services	1.7501 of 5 stars	$30.43 +5.0%	$23.50 -22.8%	+41.3%	$1.12B	$2.73B	N/A	2,664	Earnings Report Analyst Forecast High Trading Volume
LH Labcorp	4.6908 of 5 stars	$255.12 +0.4%	$308.00 +20.7%	+1.7%	$20.84B	$13.95B	22.60	71,000	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DGX) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and DVA

How does Quest Diagnostics compare to Henry Schein?

Summary

How does Quest Diagnostics compare to Medpace?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Summary

How does Quest Diagnostics compare to Labcorp?

Summary

How does Quest Diagnostics compare to DaVita?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quest Diagnostics (DGX) Competitors

DGX vs. HSIC, MEDP, AMN, LH, and DVA

How does Quest Diagnostics compare to Henry Schein?

Which has better valuation & earnings, HSIC or DGX?

Is HSIC or DGX more profitable?

Which has more volatility & risk, HSIC or DGX?

Do insiders & institutionals believe in HSIC or DGX?

Do analysts recommend HSIC or DGX?

Does the media refer more to HSIC or DGX?

Summary

How does Quest Diagnostics compare to Medpace?

Which has stronger valuation & earnings, MEDP or DGX?

Does the media favor MEDP or DGX?

Do insiders and institutionals hold more shares of MEDP or DGX?

Is MEDP or DGX more profitable?

Do analysts prefer MEDP or DGX?

Which has more volatility and risk, MEDP or DGX?

Summary

How does Quest Diagnostics compare to AMN Healthcare Services?

Do analysts prefer AMN or DGX?

Which has higher valuation and earnings, AMN or DGX?

Does the media refer more to AMN or DGX?

Do institutionals and insiders hold more shares of AMN or DGX?

Which has more risk and volatility, AMN or DGX?

Is AMN or DGX more profitable?

Summary

How does Quest Diagnostics compare to Labcorp?

Does the media prefer DGX or LH?

Which has more volatility and risk, DGX or LH?

Is DGX or LH more profitable?

Which has preferable valuation and earnings, DGX or LH?

Do institutionals & insiders believe in DGX or LH?

Is DGX or LH a better dividend stock?

Do analysts prefer DGX or LH?

Summary

How does Quest Diagnostics compare to DaVita?

Which has more volatility & risk, DGX or DVA?

Does the media prefer DGX or DVA?

Do institutionals & insiders believe in DGX or DVA?

Do analysts recommend DGX or DVA?

Which has stronger earnings and valuation, DGX or DVA?

Is DGX or DVA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DGX vs. The Competition

Quest Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools